Back to Search Start Over

Leukotriene D4 Levels in Patıents With Breast Cancer

Authors :
AKAYDIN, Sevgi
RAMAZANOĞLU, Sümeyye
MİSER SALİHOĞLU, Ece
KARANLIK, Hasan
DEMOKAN, Semra
Source :
Volume: 47, Issue: 3 331-338, Fabad Eczacılık Bilimler Dergisi, Fabad Journal of Pharmaceutical Sciences
Publication Year :
2022
Publisher :
FABAD Farmasotik Bilimler Ankara Dernegi, 2022.

Abstract

Leukotriene D4 (LTD4) is an inflammatory mediator synthesized in the arachidonic acid pathway and has been reported to induce cell proliferation and survival in cancer. LTD4 is synthesized from LTC4 by the enzyme gamma-glutamyltransferase (GGT). Here, we examined serum LTD4 levels and the relationship of LTD4 with GGT in patients with breast cancer. For that purpose, serum samples were taken from 43 patients diagnosed with breast cancer and 8 healthy controls. The patients were divided into five subgroups, as Luminal A, Luminal B, Luminal B-HER2(+), HER2(+) and triple negative. LTD4 levels were measured by ELISA method. Mean levels of LTD4 in the patients were significantly higher than in healthy controls [3,43 (2,21) ng/mL vs 1,47 (0,46) ng/mL; p < 0.05]. According to the molecular subtypes, serum LTD4 levels were found to be significantly higher in the Luminal A, Luminal B and Triple (-) subgroups than in the controls (p

Details

ISSN :
13004182 and 26514648
Database :
OpenAIRE
Journal :
Fabad Journal of Pharmaceutical Sciences
Accession number :
edsair.doi.dedup.....6997a171af18a8f0f7abc19c34392394
Full Text :
https://doi.org/10.55262/fabadeczacilik.1086291